Filing Analysis
Codexis, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal notice that earnings data has been released via press release.
📋 Key Facts
- Reporting date: August 11, 2026
- Period covered: Quarter ended June 30, 2026
- The company furnished Exhibit 99.1 containing the full text of the press release.
- Signed by Georgia Erbez, CFO and Chief Business Officer.
Codexis, Inc. completed a public offering of 16,666,667 shares of common stock at $1.50 per share, resulting in approximately $23.1 million in net proceeds. The offering was conducted via an underwriting agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co.
🚩 Red Flags
- Significant dilution: Issuance of over 16 million shares at a low price point ($1.50) suggests substantial dilution for existing shareholders.
- Potential liquidity need: The scale of the offering often indicates a requirement for immediate working capital or debt reduction.
📋 Key Facts
- Total shares issued: 16,666,667 common stock shares.
- Offering price: $1.50 per share.
- Net proceeds to company: Approximately $23.1 million (after discounts and expenses).
- Underwriters include Piper Sandler & Co. and Cantor Fitzgerald & Co.
- The offering was conducted under an effective shelf registration statement on Form S-3 (No. 333-279082).
- Includes a 90-day lock-up period for directors and executive officers regarding existing holdings.
Codexis, Inc. has released preliminary financial results for the second quarter of 2026. The company expects to report revenue of at least $14.8 million and a cash position of approximately $54.9 million as of June 30, 2026.
🚩 Red Flags
- Preliminary nature of the data; actual results may vary significantly from these estimates.
📋 Key Facts
- Expected total revenue for the three months ended June 30, 2026: at least $14.8 million.
- Expected cash, cash equivalents, and short-term investments as of June 30, 2026: approximately $54.9 million.
- Figures are preliminary estimates subject to completion of financial closing procedures.
Codexis, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026. The meeting resulted in the election of three directors and the ratification of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 17, 2026.
- Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi were elected to the Board of Directors for terms expiring in 2029.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Stockholders approved executive compensation on a non-binding advisory basis.
Codexis, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made through a press release furnished as an exhibit to the Form 8-K.
📋 Key Facts
- The filing was made on May 7, 2026, to report results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The financial information was furnished as Exhibit 99.1 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by Georgia Erbez, Chief Financial Officer and Chief Business Officer.
Dennis Wolf resigned from the Board of Directors and its committees on April 8, 2026, without disagreement. Following the resignation, the Board performed a technical rebalancing of its classes, involving the resignation and immediate re-election of Dr. Esther Martinborough to a different class.
📋 Key Facts
- Dennis Wolf resigned from the Board, Audit Committee, and Compensation Committee effective April 8, 2026.
- The resignation was not the result of any disagreement with the Company on operations, policies, or practices.
- On April 10, 2026, Dr. Esther Martinborough resigned as a Class II director and was immediately re-elected as a Class III director.
- The Class Rebalance was conducted to achieve an equal distribution of three directors per class across the three Board classes.
- Dr. Martinborough retains her roles on the Compensation, Strategy, and Science & Technology Committees.
Codexis, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025.
📋 Key Facts
- The report was filed on March 11, 2026.
- Financial results cover the period ended December 31, 2025.
- The announcement was made via a press release furnished as Exhibit 99.1.
- The filing was signed by Georgia Erbez, Chief Financial Officer and Chief Business Officer.
Codexis, Inc. announced a major leadership transition and significant restructuring, including the appointment of Dr. Alison Moore as new CEO and a 24% workforce reduction to focus on its ECO Synthesis platform.
🚩 Red Flags
- Significant workforce reduction (24%) indicates aggressive cost-cutting/restructuring.
- Multiple executive departures and leadership changes occurring simultaneously.
- Restructuring costs expected to impact Q4 2025 financial results.
📋 Key Facts
- Dr. Alison Moore appointed President and CEO, effective November 7, 2025, replacing Stephen Dilly.
- Implementation of a workforce reduction affecting approximately 24% of employees.
- Expected restructuring charge of approximately $3.5 million to be recognized in Q4 2025.
- COO Kevin Norrett is ceasing his role and entering into a consulting agreement through November 6, 2026.
- Stephen Dilly will remain as Chair of the Board.
Codexis, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings and includes the related press release as an exhibit.
📋 Key Facts
- Report date: August 13, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing contains results of operations and financial condition under Item 2.02
- Press release issued as Exhibit 99.1
Codexis, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on June 10, 2025. Key outcomes included the election of two directors and stockholder approval for an amendment to the company's 2019 Incentive Award Plan.
🚩 Red Flags
- Significant opposition to Proposal 4 (Incentive Award Plan amendment), with 14,328,338 votes against compared to 39,906,994 for.
📋 Key Facts
- Annual Meeting held on June 10, 2025.
- Stockholders approved adding 8,000,000 shares of Common Stock to the 2019 Incentive Award Plan.
- David V. Smith and Dennis P. Wolf were elected to three-year terms expiring in 2028.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Non-binding advisory vote (Say-on-Pay) on executive compensation was approved.
Codexis, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and includes the press release as Exhibit 99.1.
📋 Key Facts
- Reporting date: May 14, 2025
- Period covered: Quarter ended March 31, 2025
- The filing contains results of operations and financial condition under Item 2.02
- Press release issued as Exhibit 99.1
Codexis, Inc. announced that Byron L. Dorgan has provided notice of his intention to retire from the Board of Directors at the conclusion of his current term during the 2025 Annual Meeting of Stockholders.
📋 Key Facts
- Byron L. Dorgan will not stand for reelection at the 2025 Annual Meeting of Stockholders.
- The departure is a planned retirement and not due to any disagreement with the Company's operations, policies, or practices.
- Mr. Dorgan will continue to serve as a director until the expiration of his term at the upcoming annual meeting.
Codexis, Inc. announced the appointment of Cynthia Collins to its Board of Directors as a Class II director and a member of the Compensation Committee, effective March 28, 2025.
📋 Key Facts
- Cynthia Collins appointed as Class II Director, effective March 28, 2025.
- Ms. Collins will serve on the Compensation Committee.
- Board determined Ms. Collins is independent per Nasdaq Listing Rule 5605.
- Annual cash retainer: $50,000 for Board service; $20,000 for Compensation Committee service.
- Grant of restricted stock units (RSUs) valued at $200,000 based on the March 28, 2025 closing price of $2.81 per share.
- Automatic annual grant of RSUs valued at $100,000 on each annual meeting date.
Codexis, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal notice of the earnings release issued on February 27, 2025.
📋 Key Facts
- Reporting period: Quarter and year ended December 31, 2024.
- Filing date: February 27, 2025.
- The filing includes a press release (Exhibit 99.1) containing the full financial results.
Codexis, Inc. announced the appointment of Christos Richards to its Board of Directors as a Class II director, effective January 14, 2025. Mr. Richards will also serve on the Nominating and Corporate Governance Committee and the Strategy Committee.
📋 Key Facts
- Christos Richards appointed as Class II director effective Jan 14, 2025.
- Appointed to Nominating and Corporate Governance Committee and Strategy Committee.
- Annual cash retainer: $50,000 for Board service; $10,000 each for committee service.
- RSU grant: $200,000 worth of units based on Jan 14 closing price of $4.53/share.
- Automatic annual RSU grant of $100,000 worth of shares at the annual meeting.
Codexis, Inc. announced the appointment of Dr. Raymond De Vré to its Board of Directors and Science and Technology Committee, effective November 7, 2024. The company also adopted amendments to its Second Amended and Restated Bylaws to align with Delaware law.
📋 Key Facts
- Dr. Raymond De Vré appointed as Class I director, effective Nov 7, 2024.
- Dr. De Vré will serve on the Science and Technology Committee.
- Director compensation includes a $50,000 annual cash retainer and $10,000 for committee service.
- Grant of restricted stock units (RSUs) valued at $200,000 based on the Nov 7 closing price of $4.18 per share.
- Bylaws amended to align with Delaware law and update stockholder nomination/meeting procedures.
Codexis, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal notice that earnings data is being released via press release.
📋 Key Facts
- Report date: October 31, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the full text of the earnings press release.
- Item 2.02 was used to report results of operations and financial condition.
Codexis, Inc. announced the departure of Sriram Ryali as Chief Financial Officer and principal financial/accounting officer, effective September 30, 2024. The filing details a separation agreement including severance benefits and a transitional consulting arrangement.
🚩 Red Flags
- Departure of a key executive (CFO) following a change in control context.
- Potential for leadership instability during a transitional phase.
📋 Key Facts
- Sriram Ryali ceased serving as CFO and principal financial/accounting officer on September 30, 2024.
- The departure is characterized as a qualifying termination under a Change of Control Severance Agreement dated January 27, 2023.
- Mr. Ryali will receive severance benefits and a bonus equal to 75% of his target bonus for fiscal year 2024.
- A Separation and Consulting Agreement was entered into on October 16, 2024.
- Mr. Ryali will provide transitional consulting services on an as-needed basis until February 28, 2025.
- Outstanding equity awards will continue to vest based on continued service during the consulting period.
Codexis, Inc. announced a significant leadership reshuffle effective September 30, 2024, involving the appointment of a new Chief Technical Officer and Chief Financial Officer, alongside the departure of a Board member.
🚩 Red Flags
- Simultaneous departure of a Board member and the CFO suggests significant management turnover.
- The inclusion of specific 'Change of Control' severance enhancements for new hires may indicate the company is positioning itself for or anticipating an M&A event.
📋 Key Facts
- Dr. Alison Moore appointed as Chief Technical Officer; simultaneously resigned from the Board and its committees (Science & Technology Committee and Compensation Committee).
- Georgia Erbez appointed as Chief Financial Officer, replacing Sriram Ryali.
- Both new executives received inducement packages including 300,000 stock options and 50,000 RSUs each.
- New executives' base salaries are set at $500,000 with a 50% target bonus opportunity.
- Change of Control/Severance agreements were established for both new officers, including enhanced protections (18 months severance) if terminated near a change of control event.
Codexis, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice that the company's quarterly earnings press release has been issued.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Filing date: August 8, 2024
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Codexis, Inc. reported the final results of its 2024 annual meeting of stockholders held on June 11, 2024. The meeting included the election of two directors and the ratification of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 11, 2024.
- Esther Martinborough elected to a three-year term expiring in 2027.
- H. Stewart Parker elected to a three-year term expiring in 2027.
- KPMG LLP ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Non-binding advisory vote (Say-on-Pay) on executive compensation was approved.
Codexis, Inc. announced a technical milestone regarding the enzymatic synthesis of full-length oligonucleotides to support RNA-based therapeutics manufacturing. The announcement coincides with a presentation at the TIDES USA annual meeting.
📋 Key Facts
- Successfully synthesized a full-length oligonucleotide from starter material via an enzymatic route.
- The process involves the attachment of a conjugation moiety to support RNA-based therapeutics manufacturing.
- Data was presented at the TIDES USA annual meeting in Boston, MA (May 14–17, 2024).
Codexis, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Filing date: May 2, 2024
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
Codexis, Inc. announced the dismissal of BDO USA, P.C. as its independent registered public accounting firm and the appointment of KPMG LLP for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Auditor change (dismissal of previous firm).
📋 Key Facts
- Dismissal of BDO USA, P.C. effective February 29, 2024.
- Appointment of KPMG LLP as the new independent auditor for FY 2024.
- The company stated there were no disagreements with BDO regarding accounting principles or auditing procedures.
- A material weakness in internal control over financial reporting related to revenue recognition was identified in Q1 2022 but was reported as remediated by year-end 2022.
Codexis, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal notification of the earnings release issued on February 28, 2024.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Announcement date: February 28, 2024.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Codexis, Inc. announced that Jennifer Aaker, Ph.D., has notified the Board of her intention not to stand for reelection at the upcoming 2024 Annual Meeting of Stockholders. Her departure is stated to be unrelated to any disagreements with the company.
🚩 Red Flags
- None identified; the filing explicitly disclaims any disagreement between the director and the company.
📋 Key Facts
- Jennifer Aaker, Ph.D. will not seek reelection to the Board at the 2024 Annual Meeting of Stockholders.
- The decision was communicated on February 13, 2024.
- Dr. Aaker's departure is explicitly stated as NOT being due to any disagreement with the Company regarding operations, policies, or practices.
- She will continue to serve as a director until the conclusion of the 2024 Annual Meeting.
Codexis, Inc. entered into a $40 million term loan agreement with Innovatus Life Sciences Lending Fund I, LP to fund working capital and general business requirements. The deal includes an immediate $30 million tranche and the issuance of warrants for 424,028 shares of common stock.
🚩 Red Flags
- Asset-backed security: The loan is secured by 'substantially all assets' of the company, increasing lender priority in liquidation.
- Debt/Equity Dilution: Issuance of warrants for 424,028 shares represents potential dilution to existing shareholders.
📋 Key Facts
- Total Term Loan amount: up to $40.0 million.
- First tranche of $30.0 million completed on February 13, 2024.
- Second tranche of $10.0 million contingent on revenue and indebtedness-to-market cap milestones.
- Interest rate: Floating rate of (greater of Primate Rate or 7.50%) + 3.25%.
- Maturity: 5th anniversary of initial funding date.
- Warrants issued to Innovatus for 424,028 shares at an exercise price of $2.83 per share.
- Loan is secured by substantially all assets of the Company.
Codexis, Inc. has amended and restated its bylaws to modify the definition of 'Acting in Concert' and include a severability provision.
📋 Key Facts
- Board approved Amended and Restated Bylaws on February 8, 2024.
- Changes include modifications to the definition of 'Acting in Concert'.
- New provision regarding severability was added to the bylaws.
Codexis, Inc. reported unaudited pro forma cash of ~$70 million and revised its 2023 financial guidance following a $5 million upfront payment from Nestlé Health Science for the CDX-7108 product candidate.
🚩 Red Flags
- Cash runway is tied to a specific target of achieving positive cash flow by the end of 2026; failure to hit this milestone could necessitate further capital raises.
- Reliance on non-recurring upfront payments (Nestlé) to boost R&D revenue figures.
📋 Key Facts
- Reported unaudited pro forma cash and cash equivalents of approximately $70 million as of Dec 31, 2023 (includes a $5M upfront payment from Nestlé).
- Received $5 million 'CDX-7108 Payment' in January 2024 related to the Nestlé Health Science acquisition agreement.
- Revised 2023 Product Revenue guidance: expected toward upper end of $30M-$35M (excluding PAXLOVID enzyme sales).
- Revised 2023 R&D Revenue guidance: increased to $25M-$27M from previous $21M-$24M due to the Nestlé payment.
- Revised 2023 Gross Margin on product revenue: expected 60%-65% (excluding PAXLOVID), compared to previous 55%-65%.
- Company expects existing cash to fund operations until reaching positive cash flow, targeted for end of 2026.